ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2008) 16 P329

Parathyroid carcinoma treated with cinacalcet: a preliminary report

Marie Castric1, Peggy Pierre1, Julie Magnant2, Christine Chabrolle1, Caroline Mor3, Isabelle Orain4 & Pierre Lecomte1

1Endocrine Unit, University Hospital, Université F. Rabelais, 37044 Tours Cedex 9, France; 2Internal Medicine, University Hospital, Université F. Rabelais, 37044 Tours Cedex, France; 3Endocrine Surgery, University Hospital, Université F. Rabelais, 37044 Tours Cedex 9, France; 4Pathology, University Hospital, Université F. Rabelais, 37044 Tours Cedex, France.

A 61-year-old man was hospitalized for paresthesias and renal insufficiency (creatinine clearance 24 ml/min) with proteinuria. Type 2 diabetes was diagnosed in 2003 and hypertension in 2007. Hypercalcemia (4.6 mM) with normal phosphorus level 1.23 mM was discovered with very high PTH levels (863 ng/l; N<78). MIBI scintigraphy localized a right inferior parathyroid tumour. No obvious sign favouring MEN1 was observed and no familial case was reported. After a short pamidronate treatment and hydration, surgery allowed to remove the tumour and a parathyroid carcinoma was diagnosed. Post surgery PTH levels decreased to about 100 ng/l. Two months later, a thyroid right lobectomy with lymph nodes dissection was performed. No invasion was found. One month later, PTH was still high 191 ng/l with serum calcium concentration 2.18 mM and phosphorus level 0.78 mM. No hungry bone syndrome was observed and 25-OH Vit D was in the low-normal range 40 nM. SestaMIBI scintigraphy and cervical ultrasonography were normal. Eight months later PTH was very high 419 ng/l with hypercalcemia 3.3 mM and low phosphorus levels 0.52. An 18 Fluoro-FDG PET scan was normal with no fixation on bones or lungs. Creatinine clearance was 54 ml/min. After bisphosphonate and hydration without major effect (calcemia 2.88 mM), cinacalcet was begun with titration: 30 mg BID one week, 60 mg BID three weeks. Calcium levels were slightly decreased at 3 mM with low phosphorus levels: 0.38; 0.45; 0.61 mM. Cinacalcet dosage is now increased to 90 mg BID and is presently well tolerated (no nausea or vomiting noticed). Treatment titration is still going on; a new sestaMIBI scintigraphy is planned. Though emergent, Cinacalcet seems promising to control hypercalcemia in parathyroid carcinoma. Actualization of our data will be given with genetic results of HRPT2.

Article tools

My recent searches

No recent searches.